Gross margin
66.0% Fiscal year 2025
No rank: too few peers or not computed yet.
Share of revenue left after the direct cost of the products sold.
About the company
Intuitive Surgical is a US medical technology company and pioneer of surgical robots. With the da Vinci system, surgeons perform minimally invasive procedures, for example in urology, gynecology and general surgery. Revenue also comes from instruments and service per procedure. As of Oct 11, 2026
Fact sheet (from the annual report) Orthopedic and surgical supplies · Sunnyvale, USA
Intuitive Surgical offers robotic-assisted systems, instruments and accessories, training and customer service, connected through digital offerings. These include the da Vinci surgical system and Ion for bronchoscopy, for example for biopsy of small lung nodules. A network of field service engineers handles installation, repair, maintenance, round-the-clock technical support and predictive monitoring of the systems. In addition, there are digital services such as the My Intuitive app, the My Intuitive+ subscription and data analytics for hospitals. The systems are used, for example, in gallbladder removal, hernia surgery and colorectal procedures.
Automatically summarized from SEC annual report (10-K, filed Feb 3, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Price performance at a glance
Last 30 trading days
- Today −1.3%
- 7 days +1.8%
- 30 days +10.0%
- 1 year −19.1%
Day range (last trading day)
−0.5%Price at 26% of the range+1.3%
52-week range
−26.3%Price at 43% of the range+35.4%
- Distance from the all-time high
- −27.6%
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
52-week-high breakout · Analysis method
This method currently detects no pattern for ISRG. The check runs daily after the close.
You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing
What does the pattern show?
What is this? The price closes above the highest high of the last 52 weeks for the first time, on clearly higher volume. New 52-week highs are seen as a sign of strength.
This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and marginIntuitive Surgical · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 3, 2026.
Quality checks
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
Quality
Profitability, consistency, balance sheet · 2 without data
6 of 6 criteria met
Growth
Revenue and earnings per share
7 of 7 criteria met
Dividend
Level, consistency, coverage · 6 without data
0 of 1 criteria met
Financial strength
Piotroski, debt, liquidity · 2 without data
3 of 4 criteria met
Quality 6 of 6 met · 2 without data
- met: Gross margin above 40% 66.0%
- met: Operating margin above 15% 29.3%
- met: Net margin above 10% 28.4%
- met: Return on equity above 15% 16.0%
- no data: Free cash flow margin above 10% not stated in the SEC filings
- met: Profit in each of the last 5 fiscal years 5 of 5
- no data: Free cash flow positive in each of the last 3 fiscal years not stated in the SEC filings
- met: Equity ratio above 30% 87.1%
Operating margin
29.3% Fiscal year 2025
No rank: too few peers or not computed yet.
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
28.4% Fiscal year 2025
No rank: too few peers or not computed yet.
Profit after all costs, interest and taxes divided by revenue.
Return on equity
16.0% Fiscal year 2025
No rank: too few peers or not computed yet.
Net income divided by equity at fiscal year end.
Return on assets
14.0% Fiscal year 2025 (total assets at year end)
No rank: too few peers or not computed yet.
Net income divided by total assets at fiscal year end.
Equity ratio
87.1% Fiscal year 2025
No rank: too few peers or not computed yet.
Equity as a share of total assets. Usually low for banks.
Growth 7 of 7 met
- met: Over 3 years, revenue grew by more than 5% per year +17.4%
- met: Over 5 years, revenue grew by more than 5% per year +18.2%
- met: Over 10 years, revenue grew by more than 5% per year +15.5%
- met: Over 3 years, EPS grew by more than 5% per year +29.2%
- met: Over 5 years, EPS grew by more than 5% per year +21.8%
- met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
- met: Revenue rose in the last fiscal year +20.5%
Revenue growth 3 years
+17.4% per year
No rank: too few peers or not computed yet.
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+18.2% per year
No rank: too few peers or not computed yet.
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+15.5% per year
No rank: too few peers or not computed yet.
Average growth per year over 10 fiscal years.
EPS growth 3 years
+29.2% per year
No rank: too few peers or not computed yet.
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 5 years
+21.8% per year
No rank: too few peers or not computed yet.
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 10 years
+16.4% per year
No rank: too few peers or not computed yet.
Growth of earnings per share per year, adjusted for stock splits.
Dividend 0 of 1 met · 6 without data
- not met: Pays a dividend no dividend per share reported for the last fiscal year
- no data: Payout ratio at most 60% of earnings pays no dividend
- no data: Dividend paid in each of the last 5 fiscal years pays no dividend
- no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
- no data: Dividend per share higher than 5 years ago pays no dividend
- no data: Free cash flow per share covers the dividend pays no dividend
- no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend
Financial strength 3 of 4 met · 2 without data
- not met: Piotroski F-Score at least 7 of 9 5 of 8 · 1 without data
- no data: Long-term debt no higher than equity no long-term debt reported
- met: Current assets cover current liabilities 4.87
- met: Positive equity 17.8B USD
- met: In 5 years, share count up by at most 5% +0.5%
- no data: Free cash flow positive in the last fiscal year capital expenditure or operating cash flow not reported
Piotroski F-Score
5 of 8 Fiscal year 2025
No rank: not all 9 criteria have data.
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Liquidity (current ratio)
4.87 at fiscal year end
No rank: too few peers or not computed yet.
Current assets divided by current liabilities.
Change in share count
+0.5% in 5 years
No rank: too few peers or not computed yet.
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
- met: Profit in the last fiscal year (positive return on assets)
- met: Positive operating cash flow
- met: Return on assets higher than the prior year
- met: Operating cash flow higher than net income
- no data: Long-term debt relative to total assets fell
- met: Liquidity (current assets / current liabilities) rose
- not met: No additional shares (diluted share count did not rise)
- not met: Gross margin higher than the prior year
- not met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock.
In short
- Light green: Revenue grew over 5 years (+18.2% per year), at least as fast as the sector median.
- Light green: Net income (total) grew over 5 years (+21.9% per year), at least as fast as the sector median; per share +21.8% per year.
- Light green: Net margin 28.4%, above the sector median (12.9%).
- Light green: Profit in each of the last 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 2.7B USD · Net income 735.9M USD · Net margin 27.2%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 3.1B USD · Net income 660.0M USD · Net margin 21.0%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 3.7B USD · Net income 1.1B USD · Net margin 30.3%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 4.5B USD · Net income 1.4B USD · Net margin 30.8%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 4.4B USD · Net income 1.1B USD · Net margin 24.3%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 5.7B USD · Net income 1.7B USD · Net margin 29.9%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 6.2B USD · Net income 1.3B USD · Net margin 21.3%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 7.1B USD · Net income 1.8B USD · Net margin 25.2%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 8.4B USD · Net income 2.3B USD · Net margin 27.8%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 10.1B USD · Net income 2.9B USD · Net margin 28.4%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 1.9B USD · Net income 606.2M USD · Net margin 31.4% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 1.9B USD · Net income 544.9M USD · Net margin 28.8%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 2.0B USD · Net income 526.9M USD · Net margin 26.2%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 2.0B USD · Net income 565.1M USD · Net margin 27.7%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 2.4B USD · Net income 685.7M USD · Net margin 28.4% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 2.3B USD · Net income 698.4M USD · Net margin 31.0%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 2.4B USD · Net income 658.4M USD · Net margin 27.0%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 2.5B USD · Net income 704.4M USD · Net margin 28.1%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 2.9B USD · Net income 794.8M USD · Net margin 27.7% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 2.8B USD · Net income 821.5M USD · Net margin 29.6%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 2.9B USD · Net income 818.1M USD · Net margin 28.3%
- Quarter Q3/26 (Jul 1, 2026 – Sep 30, 2026): Revenue 3.0B USD · Net income 522.8M USD · Net margin 17.1%
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share 2.08 USD (adjusted for split 3:1, 3:1)
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 1.89 USD (adjusted for split 3:1)
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 3.16 USD (adjusted for split 3:1)
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 3.85 USD (adjusted for split 3:1)
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 2.94 USD (adjusted for split 3:1)
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 4.66 USD
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 3.65 USD
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 5.03 USD
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share 6.42 USD
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 7.87 USD
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share not reported separately for Q4
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share 1.51 USD
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share 1.46 USD
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Earnings per share 1.56 USD
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Earnings per share not reported separately for Q4
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Earnings per share 1.92 USD
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Earnings per share 1.81 USD
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Earnings per share 1.95 USD
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 2.28 USD
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 2.29 USD
- Quarter Q3/26 (Jul 1, 2026 – Sep 30, 2026): Earnings per share 1.49 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 10.1B USD · Net income 2.9B USD · Net margin 28.4%
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 66.0 USD gross profit, 29.3 USD operating income and 28.4 USD net income remained.
Money flow as a table
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 10.1B USD | 100.0% |
| Gross profit | 6.6B USD | 66.0% |
| Cost of revenue | 3.4B USD | 34.0% |
| Operating income | 2.9B USD | 29.3% |
| Research & development | 1.3B USD | 13.0% |
| Other operating expenses | 2.4B USD | 23.7% |
| Net income | 2.9B USD | 28.4% |
| Taxes, interest & other | 89.5M USD | 0.9% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Margins
The operating margin rose in 5 years from 24.1% to 29.3%.
Gross marginOperating marginNet margin- Fiscal year 2016: Gross margin 69.8% · Operating margin 34.9% · Net margin 27.2%
- Fiscal year 2017: Gross margin 69.9% · Operating margin 33.6% · Net margin 21.0%
- Fiscal year 2018: Gross margin 69.9% · Operating margin 32.2% · Net margin 30.3%
- Fiscal year 2019: Gross margin 69.4% · Operating margin 30.7% · Net margin 30.8%
- Fiscal year 2020: Gross margin 65.6% · Operating margin 24.1% · Net margin 24.3%
- Fiscal year 2021: Gross margin 69.3% · Operating margin 31.9% · Net margin 29.9%
- Fiscal year 2022: Gross margin 67.4% · Operating margin 25.3% · Net margin 21.3%
- Fiscal year 2023: Gross margin 66.4% · Operating margin 24.8% · Net margin 25.2%
- Fiscal year 2024: Gross margin 67.5% · Operating margin 28.1% · Net margin 27.8%
- Fiscal year 2025: Gross margin 66.0% · Operating margin 29.3% · Net margin 28.4%
Returns
Return on equity rose in 5 years from 10.9% to 16.0%.
Return on equityReturn on assets- Fiscal year 2016: Return on equity 12.7% · Return on assets 11.3%
- Fiscal year 2017: Return on equity 14.0% · Return on assets 11.5%
- Fiscal year 2018: Return on equity 16.9% · Return on assets 14.4%
- Fiscal year 2019: Return on equity 16.7% · Return on assets 14.2%
- Fiscal year 2020: Return on equity 10.9% · Return on assets 9.5%
- Fiscal year 2021: Return on equity 14.3% · Return on assets 12.6%
- Fiscal year 2022: Return on equity 12.0% · Return on assets 10.2%
- Fiscal year 2023: Return on equity 13.5% · Return on assets 11.6%
- Fiscal year 2024: Return on equity 14.1% · Return on assets 12.4%
- Fiscal year 2025: Return on equity 16.0% · Return on assets 14.0%
Equity and long-term debt
The equity ratio stayed roughly the same in 5 years (87.1%).
Equity in USD Long-term debt, depending on the filing, includes the current portion or leases.- Fiscal year 2016: Equity 5.8B USD
- Fiscal year 2017: Equity 4.7B USD
- Fiscal year 2018: Equity 6.7B USD
- Fiscal year 2019: Equity 8.3B USD
- Fiscal year 2020: Equity 9.7B USD
- Fiscal year 2021: Equity 11.9B USD
- Fiscal year 2022: Equity 11.0B USD
- Fiscal year 2023: Equity 13.3B USD
- Fiscal year 2024: Equity 16.4B USD
- Fiscal year 2025: Equity 17.8B USD
Liquidity (current ratio)
The current ratio fell in 5 years from 6.86 to 4.87.
Current ratio- Fiscal year 2016: Current ratio 5.45
- Fiscal year 2017: Current ratio 3.99
- Fiscal year 2018: Current ratio 5.28
- Fiscal year 2019: Current ratio 4.53
- Fiscal year 2020: Current ratio 6.86
- Fiscal year 2021: Current ratio 5.08
- Fiscal year 2022: Current ratio 4.40
- Fiscal year 2023: Current ratio 4.76
- Fiscal year 2024: Current ratio 4.07
- Fiscal year 2025: Current ratio 4.87
Cash flow
Operating cash flow rose in 5 years from 1.5B USD to 3.0B USD.
Operating cash flow in USD- Fiscal year 2016: Operating cash flow 1.0B USD
- Fiscal year 2017: Operating cash flow 1.1B USD
- Fiscal year 2018: Operating cash flow 1.2B USD
- Fiscal year 2019: Operating cash flow 1.6B USD
- Fiscal year 2020: Operating cash flow 1.5B USD
- Fiscal year 2021: Operating cash flow 2.1B USD
- Fiscal year 2022: Operating cash flow 1.5B USD
- Fiscal year 2023: Operating cash flow 1.8B USD
- Fiscal year 2024: Operating cash flow 2.4B USD
- Fiscal year 2025: Operating cash flow 3.0B USD
Share count
The share count stayed roughly the same in 5 years.
Diluted share count- Fiscal year 2016: Diluted share count 353.7M
- Fiscal year 2017: Diluted share count 348.9M
- Fiscal year 2018: Diluted share count 356.4M
- Fiscal year 2019: Diluted share count 358.5M
- Fiscal year 2020: Diluted share count 360.9M
- Fiscal year 2021: Diluted share count 365.8M
- Fiscal year 2022: Diluted share count 362.0M
- Fiscal year 2023: Diluted share count 357.4M
- Fiscal year 2024: Diluted share count 362.0M
- Fiscal year 2025: Diluted share count 362.7M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
- Dividend per share
- none pays no dividend
- Share count over 5 years
- +0.5% roughly unchanged
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+18.2% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 18.2% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+21.9% per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: +21.8% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 21.9% per year on average – at least as fast as the median company in the sector (+7.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net margin
Profit marginThe share of revenue that is left as profit after all costs.Example: Profit €60m on €500m revenue → margin 12%.More in the Academy: Lesson revenue, profit and margin28.4% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue, 28.38 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 24.3%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth– latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin10 of 10 fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
All figures as a table
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 10.1B | 2.9B | 28.4% | 7.87 | – | – |
| 2024 | Dec 31, 2024 | 8.4B | 2.3B | 27.8% | 6.42 | – | – |
| 2023 | Dec 31, 2023 | 7.1B | 1.8B | 25.2% | 5.03 | – | – |
| 2022 | Dec 31, 2022 | 6.2B | 1.3B | 21.3% | 3.65 | – | – |
| 2021 | Dec 31, 2021 | 5.7B | 1.7B | 29.9% | 4.66 | – | – |
| 2020 | Dec 31, 2020 | 4.4B | 1.1B | 24.3% | 2.94 | – | – |
| 2019 | Dec 31, 2019 | 4.5B | 1.4B | 30.8% | 3.85 | – | – |
| 2018 | Dec 31, 2018 | 3.7B | 1.1B | 30.3% | 3.16 | – | – |
| 2017 | Dec 31, 2017 | 3.1B | 660.0M | 21.0% | 1.89 | – | – |
| 2016 | Dec 31, 2016 | 2.7B | 735.9M | 27.2% | 2.08 | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q3/26 | Sep 30, 2026 | 3.0B | 522.8M | 17.1% | 1.49 | – | – |
| Q2/26 | Jun 30, 2026 | 2.9B | 818.1M | 28.3% | 2.29 | – | – |
| Q1/26 | Mar 31, 2026 | 2.8B | 821.5M | 29.6% | 2.28 | – | – |
| Q4/25* | Dec 31, 2025 | 2.9B | 794.8M | 27.7% | – | – | – |
| Q3/25 | Sep 30, 2025 | 2.5B | 704.4M | 28.1% | 1.95 | – | – |
| Q2/25 | Jun 30, 2025 | 2.4B | 658.4M | 27.0% | 1.81 | – | – |
| Q1/25 | Mar 31, 2025 | 2.3B | 698.4M | 31.0% | 1.92 | – | – |
| Q4/24* | Dec 31, 2024 | 2.4B | 685.7M | 28.4% | – | – | – |
| Q3/24 | Sep 30, 2024 | 2.0B | 565.1M | 27.7% | 1.56 | – | – |
| Q2/24 | Jun 30, 2024 | 2.0B | 526.9M | 26.2% | 1.46 | – | – |
| Q1/24 | Mar 31, 2024 | 1.9B | 544.9M | 28.8% | 1.51 | – | – |
| Q4/23* | Dec 31, 2023 | 1.9B | 606.2M | 31.4% | – | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Per-share values adjusted for stock split Stock splitA company divides each share into several new ones; the value of the company stays the same. We convert per-share values from before the split to today’s scale.Example: Split 4 : 1, earnings per share before $11.89 → comparable today $2.97.More in the Academy: Lesson revenue, profit and margin 3:1 (between Jul 21, 2017 and Oct 20, 2017), 3:1 (between Jul 21, 2021 and Oct 20, 2021). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $16.9M7 people | −$16.9M |
| 6 months | $00 people | $20.0M8 people | −$20.0M |
| 12 months | $00 people | $70.9M11 people | −$70.9M |
Latest transactions
- Oct 23, 2026 Widman Fredrik Officer Open-market sale · 10b5-1 plan 4,047 shares · $1.8M · SEC
- Oct 23, 2026 Guthart Gary S Director Open-market sale · 10b5-1 plan 20,095 shares · $9.1M · SEC
- Oct 23, 2026 Barratt Craig H Director Open-market sale · 10b5-1 plan 1,150 shares · $510.4K · SEC
- Oct 23, 2026 Wadors Patricia L Officer Open-market sale · 10b5-1 plan 1,078 shares · $478.4K · SEC
- Sep 15, 2026 Widman Fredrik Officer Open-market sale · 10b5-1 plan 543 shares · $203.3K · SEC
- Sep 15, 2026 Widman Fredrik Officer Open-market sale · 10b5-1 plan 546 shares · $204.4K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +25
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200-20
ADX (trend strength)+0
Highs and lows+0
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)15.4
Rel. strength 60 d+17.6%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
More stocks from Health Care
News
Latest news
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests Yahoo Finance · Oct 27, 16:31
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views? Yahoo Finance · Oct 27, 13:30
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views? Finnhub · Yahoo · Oct 27, 13:30
2 large-cap stocks for long-term investors and 1 we brush off Yahoo Finance · Oct 26, 21:22
2 large-cap stocks for long-term investors and 1 we brush off Finnhub · Yahoo · Oct 26, 21:22
Intuitive Surgical (ISRG) is an Incredible Growth Stock: 3 Reasons Why Yahoo Finance · Oct 26, 16:45
Intuitive Surgical (ISRG) is an Incredible Growth Stock: 3 Reasons Why Finnhub · Yahoo · Oct 26, 16:45
Earnings Estimates Moving Higher for Intuitive Surgical (ISRG): Time to Buy? Yahoo Finance · Oct 26, 16:20
Posts
No posts on ISRG yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules